Charles River Laboratories lands Morgan Stanley upgrade, shares in S&P 500 medtech spotlight

Morgan Stanley has turned more positive on Charles River Laboratories, upgrading the stock amid improving biopharma funding and new AI-enabled drug discovery partnerships.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 19:27.

Charles River Laboratories International (US1591881009) sits in focus today after a fresh analyst upgrade tied to biopharma funding trends and new AI-driven discovery collaborations. The stock trades on the NYSE and is a constituent of the S&P 500 healthcare cohort, giving the move sector relevance as Morgan Stanley turns more positive on the name. Morgan Stanley upgrade summary via Intellectia.ai

What Morgan Stanley changes

Morgan Stanley recently upgraded Charles River, citing a recovery in biopharma funding that supports spending on outsourced preclinical services. Analyst note synopsis referencing Seeking Alpha The bank's model now reflects a higher fair value, with CRL highlighted alongside IQVIA as a key beneficiary of renewed capital flows into drug development. Twelve Wall Street analysts currently cover Charles River, with a majority rating the shares Buy and the rest Hold, pointing to a broadly constructive consensus on the medium term outlook. Consensus data snapshot on MarketBeat

The Morgan Stanley view aligns with independent valuation work that sees upside from current levels. Simply Wall St cites a fair value estimate around 215 dollars per share based on forecasts for approximately 4.4 billion dollars in revenue and 483 million dollars in earnings by 2028, implying mid single digit percentage upside from recent prices. Simply Wall St valuation discussion Some more cautious analysts still project flatter revenue around 4.0 billion dollars and lower earnings into 2029, but the Morgan Stanley upgrade underscores that the risk/reward is now seen more favorably as funding conditions normalize.

Consensus and recent share performance

CRL shares recently changed hands around the 200 dollar mark on US trading platforms, after opening near 191 dollars earlier in the day. Robinhood intraday quote for CRL MarketBeat data shows the stock at roughly 207 dollars in late morning trading, representing a gain of about 2.6 percent on the session and placing the market capitalization close to 10 billion dollars. MarketBeat price and market cap metrics The valuation sits in the mid twenty times forward earnings range on many analyst models, a level that reflects both the defensive nature of laboratory outsourcing and the growth optionality from advanced modalities.

Analyst sentiment is broadly positive. Intellectia.ai summarizes Wall Street as having twelve active ratings on CRL, nine of which are Buy and three Hold, with an overall stance close to Strong Buy on some scales. Intellectia.ai aggregation of ratings Simply Wall St notes that more pessimistic forecasts still exist, with some houses assuming earnings near 355 million dollars by 2029, but the Morgan Stanley upgrade is one of several signals that the consensus has shifted toward a more confident growth trajectory as biopharma capital deployment resumes.

The AI collaboration with Lilly TuneLab

A significant recent operational development for Charles River is its collaboration with Eli Lilly’s Lilly TuneLab, announced on 18 June 2026. Simply Wall St coverage of Lilly TuneLab agreement Under this arrangement, Charles River will provide standardized nonclinical testing services to AI and machine learning driven drug discovery companies that use the TuneLab platform. The ecosystem is built on decades of Lilly research data, placing CRL’s services alongside large scale historical datasets and algorithmic discovery pipelines.

This linkage potentially deepens Charles River’s role in next generation preclinical research workflows, where high throughput data and sophisticated computational models increasingly guide candidate selection. The company is also aligning itself with advanced modalities beyond traditional small molecules: Simply Wall St highlights a memorandum of understanding with MEDIPOST for cell therapy testing that sits neatly next to the TuneLab agreement, framing Charles River as a key partner for complex biologics and cell-based treatments that demand stringent safety and efficacy evaluation. Discussion of MEDIPOST cell therapy collaboration

Risk factors and structural trends

Despite the constructive analyst stance and new AI-enabled partnerships, the business model carries its own set of risks. Simply Wall St notes that a faster transition toward non-animal testing methods could pressure Charles River’s core revenues, which still rely heavily on animal based preclinical work. Analysis of non-animal testing risk The company therefore needs to balance investment in alternative technologies, such as organ-on-chip or in silico models, with support for its established vivarium infrastructure.

Illuminem’s sustainability profile places Charles River in the biotechnology sector with more than 10,000 employees and annual revenue between 1 and 10 billion dollars, noting that the firm is not yet consistently profitable on some ESG frameworks. Illuminem ESG overview of Charles River Laboratory services inherently carry environmental and ethical scrutiny, especially around animal use and energy intensity of research facilities. As AI and advanced analytics gain traction, Charles River’s strategy appears to position the company as an integral part of a more data-centric, potentially less animal intensive discovery chain, but the transition will likely be gradual and closely watched by regulators and investors.

The business behind the stock

Charles River Laboratories makes its money by providing preclinical and clinical laboratory services to pharmaceutical and biotechnology companies worldwide. Illuminem description of core activities A representative service line is Discovery & Safety Assessment, where Charles River conducts nonclinical efficacy and toxicology studies for drug candidates, using both in vivo and in vitro models to generate data that support regulatory filings. The company also supplies research models, including genetically defined laboratory animals, and offers specialty testing for biologics, cell and gene therapies, and vaccines.

The working model is largely fee-for-service contracts with large pharma, emerging biotech and academic clients. As biopharma pipelines shift toward biologics, cell therapies and RNA-based modalities, the complexity of required safety packages tends to rise, which can increase the value of experienced outsourced partners. The Lilly TuneLab collaboration is one example of how Charles River aims to embed itself directly into early discovery ecosystems, capturing work at the interface of machine learning and wet lab validation. These operations underpin the revenue and earnings figures that analysts model when they set price targets and decide on rating changes such as Morgan Stanley’s recent upgrade.

Where the stock trades today

Charles River Laboratories International shares (US1591881009) trade on the NYSE. As of 2026-06-25, 11:28 Eastern, MarketBeat cites a price of 207.36 dollars per share, marking a 2.60 percent gain on the day, while Robinhood quotes the stock around 200 dollars in more recent intraday trading, with an opening print at 190.73 dollars earlier in the session.

Key data on the Charles River Laboratories shares

• Company: Charles River Laboratories International, Inc.
• ISIN: US1591881009
• WKN: 906943
• Ticker: CRL
• Trading venue: NYSE
• Price (as of 2026-06-25, 11:28 Eastern): 207.36 USD
• Market cap: approximately 9.7 billion USD (as of 2026-06-25)
• Sector / industry: Biotechnology / Medical Research Services
• Index membership: S&P 500
• Next earnings date: not officially scheduled

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security. Figures and dates are based on publicly available sources as cited and may change without notice.